JP2023526418A5 - - Google Patents

Info

Publication number
JP2023526418A5
JP2023526418A5 JP2022570478A JP2022570478A JP2023526418A5 JP 2023526418 A5 JP2023526418 A5 JP 2023526418A5 JP 2022570478 A JP2022570478 A JP 2022570478A JP 2022570478 A JP2022570478 A JP 2022570478A JP 2023526418 A5 JP2023526418 A5 JP 2023526418A5
Authority
JP
Japan
Prior art keywords
day
composition according
salt
25hc3s
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526418A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033746 external-priority patent/WO2021237146A1/en
Publication of JP2023526418A publication Critical patent/JP2023526418A/ja
Publication of JP2023526418A5 publication Critical patent/JP2023526418A5/ja
Pending legal-status Critical Current

Links

JP2022570478A 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 Pending JP2023526418A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029364P 2020-05-22 2020-05-22
US63/029,364 2020-05-22
US202063030213P 2020-05-26 2020-05-26
US63/030,213 2020-05-26
US202063113119P 2020-11-12 2020-11-12
US63/113,119 2020-11-12
US202163146556P 2021-02-05 2021-02-05
US63/146,556 2021-02-05
PCT/US2021/033746 WO2021237146A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (2)

Publication Number Publication Date
JP2023526418A JP2023526418A (ja) 2023-06-21
JP2023526418A5 true JP2023526418A5 (enExample) 2024-05-28

Family

ID=78707648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570478A Pending JP2023526418A (ja) 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置

Country Status (11)

Country Link
US (1) US20230181602A1 (enExample)
EP (1) EP4153165A4 (enExample)
JP (1) JP2023526418A (enExample)
KR (1) KR20230015940A (enExample)
CN (1) CN115803061A (enExample)
AU (1) AU2021273937A1 (enExample)
BR (1) BR112022023128A2 (enExample)
CA (1) CA3183119A1 (enExample)
MX (1) MX2022014574A (enExample)
TW (1) TW202210082A (enExample)
WO (1) WO2021237146A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298681A (en) 2016-08-02 2023-01-01 Univ Virginia Commonwealth Preparations
CN115103591B (zh) 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
CA3187310A1 (en) 2020-06-26 2021-12-30 Durect Corporation Use of oxygenated cholesterol sulfates for treating autoimmune conditions
KR20260004765A (ko) * 2024-07-02 2026-01-09 건국대학교 글로컬산학협력단 스타틴이 결합된 담즙산을 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
KR20150127599A (ko) * 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
WO2018026837A1 (en) * 2016-08-02 2018-02-08 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗

Similar Documents

Publication Publication Date Title
KR101465715B1 (ko) 심혈관 이벤트 발병 예방용 조성물
HRP20250797T1 (hr) Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom
JP2019048843A5 (enExample)
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2023527153A5 (enExample)
RU2008144136A (ru) Твердая пероральная лекарственная форма, содержащая усилитель
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
CA2251972A1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP2018508551A5 (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
JP2024507810A5 (enExample)
IL310115A (en) Treatment of his hyporesponders
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
IL274414B1 (en) Oral rifamycin sv compositions
JP2023522415A5 (enExample)
JP2023538522A5 (enExample)
WO2008011178A2 (en) Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication
US20140314844A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
JP2022177119A5 (enExample)
US20060188529A1 (en) Stable compositions of fenofibrate with fatty acid esters
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
RU2007149337A (ru) Новый способ лечения гиперлипидемии
CN102416015A (zh) 一种含他汀类药物的组合物及其用途
CN101897967A (zh) 一种治疗血脂异常的沙棘黄酮复方制剂
Brinton Newer HMG‐CoA reductase inhibitor (statin) therapies
KR20130003502A (ko) 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제